Exact Sciences Sues Geneoscopy on Patented Cologuard Cancer Tech

Exact Sciences Corp. accused Geneoscopy Inc.’s ColoSense, an at-home test for colorectal cancer screening, of infringing the Cologuard-maker’s patented methods for processing stool samples to effectively screen adults as early as age 45.

St. Louis-based Geneoscopy launched commercial sales of its ColoSense as a laboratory developed test in July 2023 and “has made clear its intention to broadly market” it to the general public upon approval by the US Food and Drug Administration, “which it expects imminently,” according to a complaint filed Friday in the US District Court for the District of Delaware.

Exact Sciences, based in Madison, Wisc., alleges ...